title: Expression of cell cycle-regulated proteins in prostate cancer.
abstract: Markers of cellular proliferation have proven to be useful prognostic markers in several tumor types. Recently, immunoreactivity for cyclins was found to provide an independent marker of tumor proliferation in breast cancer. In this study, we sought to determine the pattern of immunoreactivity for cyclins A, B, E, and Ki-67 in surgically resected prostate cancer and to determine their possible prognostic significance. Twenty-eight tumors of American Urological Association stages B and C were selected for study. Immunoreactivity for cyclins A and B was detected in most tumors and was present at significantly reduced levels as compared with breast cancer. Staining for cyclin E was present in four tumors and was present only in focal areas in two of the four. Such focal variation in expression of cell cycle regulators may reflect genetic instability in a tumor. Immunoreactivity for cyclins A and B was correlated with both Ki-67 index (the percentage of cells with Ki-67 immunoreactivity) and with each other. A Ki-67 index greater than 4.0 was associated with shorter time to prostate-specific antigen-detected relapse (P = 0.026). The fraction of cells staining for cyclins A and B divided by the fraction of cells staining for Ki-67 [(A+B)/K] was highly predictive of relapse, with values less than 0.50 associated with more rapid progression (P < 0.001). This latter result remained statistically significant after controlling for Gleason score by stratification. Our results suggest that immunoreactivity for markers of cellular proliferation may provide useful prognostic information in localized prostate cancer, and they need to be validated in a larger numbers of patients.
authors.affiliation: Division of Molecular Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: R D
authors.initials: RD
authors.lastname: Mashal
authors.forename: S
authors.initials: S
authors.lastname: Lester
authors.forename: C
authors.initials: C
authors.lastname: Corless
authors.forename: J P
authors.initials: JP
authors.lastname: Richie
authors.forename: R
authors.initials: R
authors.lastname: Chandra
authors.forename: K J
authors.initials: KJ
authors.lastname: Propert
authors.forename: A
authors.initials: A
authors.lastname: Dutta
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D000951:Antigens, Neoplasm / Q000032:analysis; D001943:Breast Neoplasms / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology; D002453:Cell Cycle; D016213:Cyclins / Q000032:analysis* / Q000096:biosynthesis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008297:Male; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000032:analysis* / Q000096:biosynthesis; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000032:analysis* / Q000096:biosynthesis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000951:Antigens, Neoplasm; D016213:Cyclins; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins